Searched for
ORCHID PHARMA OFS
China’s biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...- Debt-free Orchid Pharma charts out growth planOrchid Pharma, backed by Dhanuka Group, focuses on cephalosporin antibiotics. Expansion plans include a new facility, Enmetazobactam launch...
- Go contra as dumb money sells largecap private banks;one realty stock could double & avoid ITC: Sanjiv BhasinSanjiv Bhasin says: Insurance companies, including LIC, SBI Life, ICICI Pru, and HDFC Life, are expected to perform well in the long term. ...
- For investors with risk appetite: 4 smallcap stocks with upside potential of up to 36%The risk on trade, which essentially means taking exposure to the riskier asset class started once again. In India, this meant that once ag...
- Going for Good Stocks: Here's how Indian retail investor has grown post-pandemicIndian retail investors, especially after the Covid pandemic, have changed their investment approach. There has been a significant bolsteri...
- Biggest gainers and losers: Deepak Spinners surges 20%, Dhunseri Tea drops 10%Banking and metal stocks lifted the market.
- Biggest gainers and losers: Sugar stocks, Sona Comstar jump; Orchid Pharma tanks 10%Stellar performances by the debutants and solid buoyancy in the sugar counters stole the show.
- Orchid Pharma hits lower circuit after promoter announces OFS at 72% discountThe offer for sale opened for subscription for non-retail investors and was subscribed 1.36 per cent so far. Retail investors can bid for t...
- Orchid Pharma announces OFS at 72% discountDhanuka, which took over the pharma company under the NCLT resolution process in 2018, announced selling 32.80 lakh shares representing an ...
- Insolvency and Bankruptcy Code resolution timeline averages 440 daysAn Alvarez & Marsal India report on Thursday called upon all IBC stakeholders to focus on improving efficiency to resolve cases in a time-b...
- Market Movers: Banks, RIL help bears; some blue-chips give sell signalConcerns on the asset quality front continue to persist for many lenders despite recent signs of abating stress.
- Investors with high risk appetite can look at this theme for high returnsOne can buy shares of acquirers in the firms as NCLT cases could see a 40-70% haircuts.
- ETMarkets After Hours: BoB bleeds on NSE exclusion; pharma in painHere's a look at the major movers and shakers of D-Street through the session.
- Top pharma stocks have plunged up to 50%; time to buy on dips?Most experts said regulatory hurdles are going to be the biggest overhang for the sector and, hence, investors should remain selective.
- Sensex rangebound, Nifty tests 7550; top ten stocks in focusThe Nifty index was trading near its crucial psychological level of 7550, weighed down by losses in capital goods, autos, FMCG and pharma s...
- DIPP halts Mylan’s takeover bid for AgilaThe Department of Industrial Policy and Promotion (DIPP) has put the brakes on US-based Mylan Inc’s plan to acquire Agila Specialties.
- Markets will not recover in a hurry: Rakesh JhunjhunwalaThere is no commitment of retail investors & much lesser leverage in India & worldwide as compared to 2008 says Big Bull Rakesh Jhunjhunwal...
- Not many Indian pharma cos are left for saleIn an interview with ET, Lupin's group president Shakti Chakraborty says recent acquisitions defied logic.
- Sepracor spanner in Sun Pharma's US planUS-based drug giant Sepracor Inc and the University of Massachusetts have filed a patent infringement suit with the US district court of Ne...
- Global pharma cos may pop in buyout pillThe high-profile Mylan-Matrix deal is likely to trigger a series of mergers and acquisitions (M&A) in the Indian pharmaceutical market. Aro...
Load More
